{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,16]],"date-time":"2026-02-16T15:36:30Z","timestamp":1771256190665,"version":"3.50.1"},"reference-count":54,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2019,3,4]],"date-time":"2019-03-04T00:00:00Z","timestamp":1551657600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["World J Urol"],"published-print":{"date-parts":[[2020,3]]},"DOI":"10.1007\/s00345-019-02704-y","type":"journal-article","created":{"date-parts":[[2019,3,4]],"date-time":"2019-03-04T04:25:12Z","timestamp":1551673512000},"page":"601-611","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Timing of androgen deprivation monotherapy and combined treatments in castration-sensitive and castration-resistant prostate cancer: a narrative review"],"prefix":"10.1007","volume":"38","author":[{"given":"F.","family":"Kunath","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P. J.","family":"Goebell","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"B.","family":"Wullich","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"D.","family":"Sikic","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Kahlmeyer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2019,3,4]]},"reference":[{"issue":"1","key":"2704_CR1","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1038\/ncponc1262","volume":"6","author":"ES Antonarakis","year":"2009","unstructured":"Antonarakis ES, Eisenberger MA (2009) Is abiraterone acetate well tolerated and effective in the treatment of castration-resistant prostate cancer? Nat Clin Pract Oncol 6(1):12\u201313","journal-title":"Nat Clin Pract Oncol"},{"issue":"5928","key":"2704_CR2","doi-asserted-by":"publisher","first-page":"787","DOI":"10.1126\/science.1168175","volume":"324","author":"C Tran","year":"2009","unstructured":"Tran C, Ouk S, Clegg NJ, Chen Y, Watson PA, Arora V et al (2009) Development of a second-generation antiandrogen for treatment of advanced prostate cancer. Science 324(5928):787\u2013790","journal-title":"Science"},{"issue":"9","key":"2704_CR3","doi-asserted-by":"publisher","first-page":"945","DOI":"10.1080\/14656566.2017.1329820","volume":"18","author":"ND Shore","year":"2017","unstructured":"Shore ND (2017) Darolutamide (ODM-201) for the treatment of prostate cancer. Expert Opin Pharmacother 18(9):945\u2013952","journal-title":"Expert Opin Pharmacother"},{"issue":"6","key":"2704_CR4","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1007\/s40265-018-0900-z","volume":"78","author":"ZT Al-Salama","year":"2018","unstructured":"Al-Salama ZT (2018) Apalutamide: first global approval. Drugs 78(6):699\u2013705","journal-title":"Drugs"},{"issue":"1","key":"2704_CR5","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1159\/000479434","volume":"100","author":"PG Hammerer","year":"2018","unstructured":"Hammerer PG, Wirth MP, Group EED-NL-s (2018) Health-related quality of life in 536 long-term prostate cancer survivors after treatment with leuprorelin acetate: a combined retrospective and prospective analysis. Urol Int 100(1):72\u201378","journal-title":"Urol Int"},{"key":"2704_CR6","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1186\/1471-2407-13-131","volume":"13","author":"F Kunath","year":"2013","unstructured":"Kunath F, Keck B, Rucker G, Motschall E, Wullich B, Antes G et al (2013) Early versus deferred androgen suppression therapy for patients with lymph node-positive prostate cancer after local therapy with curative intent: a systematic review. BMC Cancer 13:131","journal-title":"BMC Cancer"},{"key":"2704_CR7","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD003506","author":"B Nair","year":"2002","unstructured":"Nair B, Wilt T, MacDonald R, Rutks I (2002) Early versus deferred androgen suppression in the treatment of advanced prostatic cancer. Cochrane Database Syst Rev. \nhttps:\/\/doi.org\/10.1002\/14651858.CD003506","journal-title":"Cochrane Database Syst Rev"},{"key":"2704_CR8","unstructured":"John Wiley & Sons Inc. (2018) Cochrane Library. \nhttps:\/\/www.cochranelibrary.com\/\n\n. Acessed date 30 Sep 2018"},{"key":"2704_CR9","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1016\/j.ejca.2017.07.003","volume":"84","author":"LHM Rydzewska","year":"2017","unstructured":"Rydzewska LHM, Burdett S, Vale CL, Clarke NW, Fizazi K, Kheoh T et al (2017) Adding abiraterone to androgen deprivation therapy in men with metastatic hormone-sensitive prostate cancer: a systematic review and meta-analysis. Eur J Cancer 84:88\u2013101","journal-title":"Eur J Cancer"},{"issue":"5","key":"2704_CR10","doi-asserted-by":"publisher","first-page":"1249","DOI":"10.1093\/annonc\/mdy071","volume":"29","author":"CL Vale","year":"2018","unstructured":"Vale CL, Fisher DJ, White IR, Carpenter JR, Burdett S, Clarke NW et al (2018) What is the optimal systemic treatment of men with metastatic, hormone-naive prostate cancer? A STOPCAP systematic review and network meta-analysis. Ann Oncol 29(5):1249\u20131257","journal-title":"Ann Oncol"},{"key":"2704_CR11","doi-asserted-by":"publisher","first-page":"516","DOI":"10.1038\/s41391-018-0055-8","volume":"21","author":"PS Tan","year":"2018","unstructured":"Tan PS, Aguiar P Jr, Haaland B, Lopes G (2018) Addition of abiraterone, docetaxel, bisphosphonate, celecoxib or combinations to androgen-deprivation therapy (ADT) for metastatic hormone-sensitive prostate cancer (mHSPC): a network meta-analysis. Prostate Cancer Prost Dis 21:516\u2013523","journal-title":"Prostate Cancer Prost Dis"},{"key":"2704_CR12","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1016\/j.ejca.2018.08.010","volume":"103","author":"S Feyerabend","year":"2018","unstructured":"Feyerabend S, Saad F, Li T, Ito T, Diels J, Van Sanden S et al (2018) Survival benefit, disease progression and quality-of-life outcomes of abiraterone acetate plus prednisone versus docetaxel in metastatic hormone-sensitive prostate cancer: a network meta-analysis. Eur J Cancer 103:78\u201387","journal-title":"Eur J Cancer"},{"issue":"5","key":"2704_CR13","doi-asserted-by":"publisher","first-page":"903","DOI":"10.1080\/03007995.2018.1447450","volume":"34","author":"L Kassem","year":"2018","unstructured":"Kassem L, Shohdy KS, Abdel-Rahman O (2018) Abiraterone acetate\/androgen deprivation therapy combination versus docetaxel\/androgen deprivation therapy combination in advanced hormone-sensitive prostate cancer: a network meta-analysis on safety and efficacy. Curr Med Res Opin 34(5):903\u2013910","journal-title":"Curr Med Res Opin"},{"issue":"3","key":"2704_CR14","doi-asserted-by":"publisher","first-page":"306","DOI":"10.1038\/s41391-017-0014-9","volume":"21","author":"M McNamara","year":"2018","unstructured":"McNamara M, Sweeney C, Antonarakis ES, Armstrong AJ (2018) The evolving landscape of metastatic hormone-sensitive prostate cancer: a critical review of the evidence for adding docetaxel or abiraterone to androgen deprivation. Prostate Cancer and prostatic Dis 21(3):306\u2013318","journal-title":"Prostate Cancer and prostatic Dis"},{"issue":"10","key":"2704_CR15","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1007\/s11934-018-0835-7","volume":"19","author":"L Xu","year":"2018","unstructured":"Xu L, Pachynski RK (2018) Contemporary management of the newly diagnosed prostate cancer patient with metastatic disease at presentation. Curr Urol Rep 19(10):79","journal-title":"Curr Urol Rep"},{"key":"2704_CR16","unstructured":"U.S. National Library of Medicine. ClinicalTrials.gov. (2018) \nhttps:\/\/www.clinicaltrials.gov\/(last\n\n. Assessed date 30 Sep 2018"},{"issue":"4","key":"2704_CR17","doi-asserted-by":"publisher","first-page":"352","DOI":"10.1056\/NEJMoa1704174","volume":"377","author":"K Fizazi","year":"2017","unstructured":"Fizazi K, Tran N, Fein L, Matsubara N, Rodriguez-Antolin A, Alekseev BY et al (2017) Abiraterone plus prednisone in metastatic, castration-sensitive prostate cancer. N Engl J Med 377(4):352\u2013360","journal-title":"N Engl J Med"},{"issue":"4","key":"2704_CR18","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1056\/NEJMoa1702900","volume":"377","author":"ND James","year":"2017","unstructured":"James ND, de Bono JS, Spears MR, Clarke NW, Mason MD, Dearnaley DP et al (2017) Abiraterone for prostate cancer not previously treated with hormone therapy. N Engl J Med 377(4):338\u2013351","journal-title":"N Engl J Med"},{"key":"2704_CR19","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD001526","author":"B Schmitt","year":"2000","unstructured":"Schmitt B, Bennett C, Seidenfeld J, Samson D, Wilt T (2000) Maximal androgen blockade for advanced prostate cancer. Cochrane Database Syst Rev. \nhttps:\/\/doi.org\/10.1002\/14651858.CD001526","journal-title":"Cochrane Database Syst Rev"},{"issue":"10","key":"2704_CR20","doi-asserted-by":"publisher","first-page":"983","DOI":"10.1016\/S1470-2045(12)70379-0","volume":"13","author":"K Fizazi","year":"2012","unstructured":"Fizazi K, Scher HI, Molina A, Logothetis CJ, Chi KN, Jones RJ et al (2012) Abiraterone acetate for treatment of metastatic castration-resistant prostate cancer: final overall survival analysis of the COU-AA-301 randomised, double-blind, placebo-controlled phase 3 study. Lancet Oncol 13(10):983\u2013992","journal-title":"Lancet Oncol"},{"issue":"21","key":"2704_CR21","doi-asserted-by":"publisher","first-page":"1995","DOI":"10.1056\/NEJMoa1014618","volume":"364","author":"JS Bono de","year":"2011","unstructured":"de Bono JS, Logothetis CJ, Molina A, Fizazi K, North S, Chu L et al (2011) Abiraterone and increased survival in metastatic prostate cancer. N Engl J Med 364(21):1995\u20132005","journal-title":"N Engl J Med"},{"issue":"2","key":"2704_CR22","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1056\/NEJMoa1209096","volume":"368","author":"CJ Ryan","year":"2013","unstructured":"Ryan CJ, Smith MR, de Bono JS, Molina A, Logothetis CJ, de Souza P et al (2013) Abiraterone in metastatic prostate cancer without previous chemotherapy. N Engl J Med 368(2):138\u2013148","journal-title":"N Engl J Med"},{"issue":"6","key":"2704_CR23","doi-asserted-by":"publisher","first-page":"831","DOI":"10.1111\/bju.13764","volume":"119","author":"MHF Poorthuis","year":"2017","unstructured":"Poorthuis MHF, Vernooij RWM, van Moorselaar RJA, de Reijke TM (2017) First-line non-cytotoxic therapy in chemotherapy-naive patients with metastatic castration-resistant prostate cancer: a systematic review of 10 randomised clinical trials. BJU Int 119(6):831\u2013845","journal-title":"BJU Int"},{"key":"2704_CR24","volume-title":"Health technology assessment of four drugs for patients with metastatic castration resistant prostate cancer","author":"I Saeterdal","year":"2016","unstructured":"Saeterdal I, Desser A, Pike E, Hamidi V, Harboe I, Odgaard-Jensen J et al (2016) Health technology assessment of four drugs for patients with metastatic castration resistant prostate cancer. NIPH Systematic Reviews. Oslo, Norway"},{"issue":"48","key":"2704_CR25","doi-asserted-by":"publisher","first-page":"84572","DOI":"10.18632\/oncotarget.20028","volume":"8","author":"RB Moreira","year":"2017","unstructured":"Moreira RB, Debiasi M, Francini E, Nuzzo PV, Velasco G, Maluf FC et al (2017) Differential side effects profile in patients with mCRPC treated with abiraterone or enzalutamide: a meta-analysis of randomized controlled trials. Oncotarget 8(48):84572\u201384578","journal-title":"Oncotarget"},{"issue":"9","key":"2704_CR26","doi-asserted-by":"publisher","first-page":"1751","DOI":"10.1007\/s00432-018-2664-y","volume":"144","author":"Y Wang","year":"2018","unstructured":"Wang Y, Zhang H, Shen W, He P, Zhou Z (2018) Effectiveness and tolerability of targeted drugs for the treatment of metastatic castration-resistant prostate cancer: a network meta-analysis of randomized controlled trials. J Cancer Res Clin Oncol 144(9):1751\u20131768","journal-title":"J Cancer Res Clin Oncol"},{"issue":"4","key":"2704_CR27","doi-asserted-by":"publisher","first-page":"690","DOI":"10.7150\/jca.22365","volume":"9","author":"Y Zhao","year":"2018","unstructured":"Zhao Y, Huang H, Chen C, Liu H, Su F, Bi J et al (2018) Efficacy and safety of different interventions in castration resistant prostate cancer progressing after docetaxel-based chemotherapy: Bayesian network analysis of randomized controlled trials. J Cancer 9(4):690\u2013701","journal-title":"J Cancer"},{"issue":"10","key":"2704_CR28","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1177\/1756287218786160","volume":"10","author":"M Marchioni","year":"2018","unstructured":"Marchioni M, Sountoulides P, Bada M, Rapisarda S, De Nunzio C, Tamburro FR et al (2018) Abiraterone in chemotherapy-naive patients with metastatic castration-resistant prostate cancer: a systematic review of \u2018real-life\u2019 studies. Ther Adv Urol 10(10):305\u2013315","journal-title":"Ther Adv Urol"},{"issue":"3","key":"2704_CR29","doi-asserted-by":"publisher","first-page":"226","DOI":"10.2174\/1574887113666180404120540","volume":"13","author":"D Tassinari","year":"2018","unstructured":"Tassinari D, Cherubini C, Roudnas B, Tamburini E, Drudi F, Bianchi E et al (2018) Treatment of metastatic, castration-resistant, docetaxel-resistant prostate cancer: a systematic review of literature with a network meta-analysis of randomized clinical trials. Rev Recent Clin Trials 13(3):226\u2013237","journal-title":"Rev Recent Clin Trials"},{"issue":"2","key":"2704_CR30","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1016\/S1470-2045(15)00518-5","volume":"17","author":"ND Shore","year":"2016","unstructured":"Shore ND, Chowdhury S, Villers A, Klotz L, Siemens DR, Phung D et al (2016) Efficacy and safety of enzalutamide versus bicalutamide for patients with metastatic prostate cancer (TERRAIN): a randomised, double-blind, phase 2 study. Lancet Oncol 17(2):153\u2013163","journal-title":"Lancet Oncol"},{"issue":"4","key":"2704_CR31","doi-asserted-by":"publisher","first-page":"320","DOI":"10.1038\/pcan.2014.24","volume":"17","author":"L Klotz","year":"2014","unstructured":"Klotz L, Drachenberg D, Singal R, Aprikian A, Fradet Y, Kebabdjian M et al (2014) An open-label, phase 2 trial of bicalutamide dose escalation from 50\u00a0mg to 150\u00a0mg in men with CAB and castration resistance. A Canadian Urology Research Consortium Study. Prostate Cancer Prost Dis 17(4):320\u2013324","journal-title":"Prostate Cancer Prost Dis"},{"issue":"13","key":"2704_CR32","doi-asserted-by":"publisher","first-page":"1187","DOI":"10.1056\/NEJMoa1207506","volume":"367","author":"HI Scher","year":"2012","unstructured":"Scher HI, Fizazi K, Saad F, Taplin ME, Sternberg CN, Miller K et al (2012) Increased survival with enzalutamide in prostate cancer after chemotherapy. N Engl J Med 367(13):1187\u20131197","journal-title":"N Engl J Med"},{"issue":"10","key":"2704_CR33","doi-asserted-by":"publisher","first-page":"1147","DOI":"10.1016\/S1470-2045(14)70303-1","volume":"15","author":"K Fizazi","year":"2014","unstructured":"Fizazi K, Scher HI, Miller K, Basch E, Sternberg CN, Cella D et al (2014) Effect of enzalutamide on time to first skeletal-related event, pain, and quality of life in men with castration-resistant prostate cancer: results from the randomised, phase 3 AFFIRM trial. Lancet Oncol 15(10):1147\u20131156","journal-title":"Lancet Oncol"},{"issue":"5","key":"2704_CR34","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1056\/NEJMoa1405095","volume":"371","author":"TM Beer","year":"2014","unstructured":"Beer TM, Armstrong AJ, Rathkopf DE, Loriot Y, Sternberg CN, Higano CS et al (2014) Enzalutamide in metastatic prostate cancer before chemotherapy. N Engl J Med 371(5):424\u2013433","journal-title":"N Engl J Med"},{"issue":"5","key":"2704_CR35","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1016\/S1470-2045(15)70113-0","volume":"16","author":"Y Loriot","year":"2015","unstructured":"Loriot Y, Miller K, Sternberg CN, Fizazi K, De Bono JS, Chowdhury S et al (2015) Effect of enzalutamide on health-related quality of life, pain, and skeletal-related events in asymptomatic and minimally symptomatic, chemotherapy-naive patients with metastatic castration-resistant prostate cancer (PREVAIL): results from a randomised, phase 3 trial. Lancet Oncol 16(5):509\u2013521","journal-title":"Lancet Oncol"},{"issue":"26","key":"2704_CR36","doi-asserted-by":"publisher","first-page":"2465","DOI":"10.1056\/NEJMoa1800536","volume":"378","author":"M Hussain","year":"2018","unstructured":"Hussain M, Fizazi K, Saad F, Rathenborg P, Shore N, Ferreira U et al (2018) Enzalutamide in Men with Nonmetastatic, Castration-Resistant Prostate Cancer. N Engl J Med 378(26):2465\u20132474","journal-title":"N Engl J Med"},{"key":"2704_CR37","doi-asserted-by":"crossref","unstructured":"Zheng H, Chen J, Qiu W, Lin S, Chen Y, Liang G, et al. (2017) Safety and efficacy of first-line treatments for chemotherapy-naive metastatic castration-resistant prostate cancer: a systematic review and indirect comparison. BioMed Res Int ID3941217:10","DOI":"10.1155\/2017\/3941217"},{"issue":"5","key":"2704_CR38","doi-asserted-by":"publisher","first-page":"358","DOI":"10.1053\/j.seminoncol.2017.10.005","volume":"44","author":"MHF Poorthuis","year":"2017","unstructured":"Poorthuis MHF, Vernooij RWM, van Moorselaar RJA, de Reijke TM (2017) Second-line therapy in patients with metastatic castration-resistant prostate cancer with progression after or under docetaxel: a systematic review of nine randomized controlled trials. Semin Oncol 44(5):358\u2013371","journal-title":"Semin Oncol"},{"issue":"15","key":"2704_CR39","doi-asserted-by":"publisher","first-page":"1408","DOI":"10.1056\/NEJMoa1715546","volume":"378","author":"MR Smith","year":"2018","unstructured":"Smith MR, Saad F, Chowdhury S, Oudard S, Hadaschik BA, Graff JN et al (2018) Apalutamide treatment and metastasis-free survival in prostate cancer. N Engl J Med 378(15):1408\u20131418","journal-title":"N Engl J Med"},{"key":"2704_CR40","doi-asserted-by":"publisher","first-page":"1404","DOI":"10.1016\/S1470-2045(18)30456-X","volume":"19","author":"F Saad","year":"2018","unstructured":"Saad F, Cella D, Basch E, Hadaschik BA, Mainwaring PN, Oudard S et al (2018) Effect of apalutamide on health-related quality of life in patients with non-metastatic castration-resistant prostate cancer: an analysis of the SPARTAN randomised, placebo-controlled, phase 3 trial. Lancet Oncol 19:1404\u20131414","journal-title":"Lancet Oncol"},{"issue":"5","key":"2704_CR41","doi-asserted-by":"publisher","first-page":"834","DOI":"10.1016\/j.eururo.2015.09.046","volume":"69","author":"C Massard","year":"2016","unstructured":"Massard C, Penttinen HM, Vjaters E, Bono P, Lietuvietis V, Tammela TL et al (2016) Pharmacokinetics, antitumor activity, and safety of ODM-201 in patients with chemotherapy-naive metastatic castration-resistant prostate cancer: an open-label phase 1 study. Eur Urol 69(5):834\u2013840","journal-title":"Eur Urol"},{"issue":"9","key":"2704_CR42","doi-asserted-by":"publisher","first-page":"1007","DOI":"10.1586\/14737140.2015.1081566","volume":"15","author":"K Fizazi","year":"2015","unstructured":"Fizazi K, Albiges L, Loriot Y, Massard C (2015) ODM-201: a new-generation androgen receptor inhibitor in castration-resistant prostate cancer. Expert Rev Anticancer Ther 15(9):1007\u20131017","journal-title":"Expert Rev Anticancer Ther"},{"issue":"5","key":"2704_CR43","doi-asserted-by":"publisher","first-page":"332","DOI":"10.1016\/j.clgc.2018.07.017","volume":"16","author":"K Fizazi","year":"2018","unstructured":"Fizazi K, Smith MR, Tombal B (2018) Clinical development of darolutamide: a novel androgen receptor antagonist for the treatment of prostate cancer. Clin Genitourin Cancer 16(5):332\u2013340. \nhttps:\/\/doi.org\/10.1016\/j.clgc.2018.07.017","journal-title":"Clin Genitourin Cancer."},{"key":"2704_CR44","unstructured":"Mottet N, van den Bergh RCN, Briers E, Bourke L, Cornford P, De Santis M, et al. (2018) EAU\u2014ESTRO\u2014ESUR\u2014SIOG Guidelines on prostate cancer. European Association of Urology. \nhttp:\/\/uroweb.org\/guideline\/prostate-cancer\/\n\n Assessed 30 Sep 2018"},{"key":"2704_CR45","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD009266.pub2","author":"F Kunath","year":"2014","unstructured":"Kunath F, Grobe HR, R\u00fccker G, Motschall E, Antes G, Dahm P, Wullich B, Meerpohl JJ (2014) Non-steroidal antiandrogen monotherapy compared with luteinising hormone-releasing hormone agonists or surgical castration monotherapy for advanced prostate cancer. Cochrane Database Syst Rev. \nhttps:\/\/doi.org\/10.1002\/14651858.CD009266.pub2","journal-title":"Cochrane Database Syst Rev"},{"key":"2704_CR46","doi-asserted-by":"publisher","first-page":"CD006145","DOI":"10.1002\/14651858.CD006145.pub3","volume":"11","author":"F Cramp","year":"2012","unstructured":"Cramp F, Byron-Daniel J (2012) Exercise for the management of cancer-related fatigue in adults. Cochrane Database Syst Rev 11:CD006145. \nhttps:\/\/doi.org\/10.1002\/14651858.CD006145.pub3","journal-title":"Cochrane Database Syst Rev"},{"issue":"2","key":"2704_CR47","first-page":"144","volume":"70","author":"M Tucci","year":"2018","unstructured":"Tucci M, Leone G, Buttigliero C, Zichi C, Di Stefano RF, Pignataro D et al (2018) Hormonal treatment and quality of life of prostate cancer patients: new evidence. Minerva Urol Nefrol 70(2):144\u2013151","journal-title":"Minerva Urol Nefrol"},{"issue":"5","key":"2704_CR48","doi-asserted-by":"publisher","first-page":"852","DOI":"10.1016\/j.eururo.2014.09.004","volume":"67","author":"P Ost","year":"2015","unstructured":"Ost P, Bossi A, Decaestecker K, De Meerleer G, Giannarini G, Karnes RJ et al (2015) Metastasis-directed therapy of regional and distant recurrences after curative treatment of prostate cancer: a systematic review of the literature. Eur Urol 67(5):852\u2013863","journal-title":"Eur Urol"},{"issue":"11","key":"2704_CR49","doi-asserted-by":"publisher","first-page":"e008217","DOI":"10.1136\/bmjopen-2015-008217","volume":"5","author":"F Kunath","year":"2015","unstructured":"Kunath F, Borgmann H, Blumle A, Keck B, Wullich B, Schmucker C et al (2015) Gonadotropin-releasing hormone antagonists versus standard androgen suppression therapy for advanced prostate cancer. a systematic review with meta-analysis. BMJ Open 5(11):e008217","journal-title":"BMJ Open"},{"issue":"2","key":"2704_CR50","doi-asserted-by":"publisher","first-page":"256","DOI":"10.1016\/j.eururo.2015.11.005","volume":"70","author":"G Gravis","year":"2016","unstructured":"Gravis G, Boher JM, Joly F, Soulie M, Albiges L, Priou F et al (2016) Androgen deprivation therapy (ADT) plus docetaxel versus adt alone in metastatic non castrate prostate cancer: impact of metastatic burden and long-term survival analysis of the randomized phase 3 GETUG-AFU15 trial. Eur Urol 70(2):256\u2013262","journal-title":"Eur Urol"},{"issue":"2","key":"2704_CR51","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1016\/S1470-2045(12)70560-0","volume":"14","author":"G Gravis","year":"2013","unstructured":"Gravis G, Fizazi K, Joly F, Oudard S, Priou F, Esterni B et al (2013) Androgen-deprivation therapy alone or with docetaxel in non-castrate metastatic prostate cancer (GETUG-AFU 15): a randomised, open-label, phase 3 trial. Lancet Oncol 14(2):149\u2013158","journal-title":"Lancet Oncol"},{"issue":"8","key":"2704_CR52","doi-asserted-by":"publisher","first-page":"737","DOI":"10.1056\/NEJMoa1503747","volume":"373","author":"CJ Sweeney","year":"2015","unstructured":"Sweeney CJ, Chen YH, Carducci M, Liu G, Jarrard DF, Eisenberger M et al (2015) Chemohormonal therapy in metastatic hormone-sensitive prostate cancer. N Engl J Med 373(8):737\u2013746","journal-title":"N Engl J Med"},{"issue":"10024","key":"2704_CR53","doi-asserted-by":"publisher","first-page":"1163","DOI":"10.1016\/S0140-6736(15)01037-5","volume":"387","author":"ND James","year":"2016","unstructured":"James ND, Sydes MR, Clarke NW, Mason MD, Dearnaley DP, Spears MR et al (2016) Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, platform randomised controlled trial. Lancet 387(10024):1163\u20131177","journal-title":"Lancet"},{"issue":"11","key":"2704_CR54","doi-asserted-by":"publisher","first-page":"1080","DOI":"10.1200\/JCO.2017.75.3657","volume":"36","author":"CE Kyriakopoulos","year":"2018","unstructured":"Kyriakopoulos CE, Chen YH, Carducci MA, Liu G, Jarrard DF, Hahn NM et al (2018) Chemohormonal therapy in metastatic hormone-sensitive prostate cancer: long-term survival analysis of the randomized phase III E3805 CHAARTED trial. J Clin Oncol 36(11):1080\u20131087","journal-title":"J Clin Oncol"}],"container-title":["World Journal of Urology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00345-019-02704-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00345-019-02704-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00345-019-02704-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,3,10]],"date-time":"2020-03-10T13:39:47Z","timestamp":1583847587000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00345-019-02704-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,3,4]]},"references-count":54,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2020,3]]}},"alternative-id":["2704"],"URL":"https:\/\/doi.org\/10.1007\/s00345-019-02704-y","relation":{},"ISSN":["0724-4983","1433-8726"],"issn-type":[{"value":"0724-4983","type":"print"},{"value":"1433-8726","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,3,4]]},"assertion":[{"value":"21 October 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 February 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 March 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"All the authors declare that they have no conflict of interest concerning the topic of this publication. The authors confirm that the project development and writing of manuscript was not funded.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This article does not contain any studies with human participants or animals performed by any of the authors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Research involving human participants and\/or animals"}},{"value":"For this type of study, formal consent is not required. All the authors have read and approved the manuscript, and it has not been submitted elsewhere. All the authors had full access to all study data and take full responsibility for the integrity of the data and the accuracy of the data analysis.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}